320 related articles for article (PubMed ID: 11023516)
1. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
[TBL] [Abstract][Full Text] [Related]
2. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
3. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.
Meij P; van Esser JW; Niesters HG; van Baarle D; Miedema F; Blake N; Rickinson AB; Leiner I; Pamer E; Lowenberg B; Cornelissen JJ; Gratama JW
Blood; 2003 Jun; 101(11):4290-7. PubMed ID: 12576337
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
6. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
7. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
8. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
9. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis.
Jilek S; Schluep M; Harari A; Canales M; Lysandropoulos A; Zekeridou A; Pantaleo G; Du Pasquier RA
J Immunol; 2012 May; 188(9):4671-80. PubMed ID: 22461701
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
11. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients.
Falco DA; Nepomuceno RR; Krams SM; Lee PP; Davis MM; Salvatierra O; Alexander SR; Esquivel CO; Cox KL; Frankel LR; Martinez OM
Transplantation; 2002 Aug; 74(4):501-10. PubMed ID: 12352909
[TBL] [Abstract][Full Text] [Related]
12. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
14. Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation.
Gandhi MK; Wills MR; Okecha G; Day EK; Hicks R; Marcus RE; Sissons JG; Carmichael AJ
Blood; 2003 Nov; 102(9):3427-38. PubMed ID: 12869514
[TBL] [Abstract][Full Text] [Related]
15. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
[TBL] [Abstract][Full Text] [Related]
16. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
19. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
[TBL] [Abstract][Full Text] [Related]
20. High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus-specific T-cell counts.
Gupta M; Kannappan S; Kalra A; Lam C; Dharmani-Khan P; Williamson T; Tellier R; Daly A; Khan FM; Storek J
Cytotherapy; 2019 Aug; 21(8):886-894. PubMed ID: 31253496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
